Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF

Pediatr Blood Cancer. 2015 Aug;62(8):1477-80. doi: 10.1002/pbc.25467. Epub 2015 Mar 8.

Abstract

Previous chemotherapy and radiation exposure can make adequate stem cell mobilisation prior to autologous transplant extremely difficult in paediatrics. Plerixafor, a selective reversible CXCR4 antagonist interferes with CXCR4 interaction with Stromal cell-derived factor 1 alpha (SDF-1). Combination with granulocyte-colony stimulating factor (G-CSF) amplifies G-CSF affects in mobilising haematopoietic stem cells. Whilst licensed for use with G-CSF for enhancement of mobilisation of haematopoietic stem cells in adults, paediatric data for use of plerixafor remain limited. We present a retrospective review of outcomes seen with plerixafor and G-CSF to mobilise stem cells heavily pre-treated paediatric patients with cancer.

Keywords: CD34 positive stem cell; children; oncology; plerixafor; stem cell mobilisation.

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Antigens, CD34 / metabolism
  • Benzylamines
  • Chemokine CXCL12 / metabolism
  • Child
  • Child, Preschool
  • Cyclams
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cells / cytology*
  • Heterocyclic Compounds / therapeutic use*
  • Humans
  • Infant
  • Male
  • Neoplasms / therapy
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, CXCR4 / metabolism
  • Retrospective Studies
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Antigens, CD34
  • Benzylamines
  • CXCL12 protein, human
  • Chemokine CXCL12
  • Cyclams
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • Granulocyte Colony-Stimulating Factor
  • plerixafor